In studies exploring unplanned switching strategies, the reported incidence of hot flashes is broadly similar to that of other studies [18 , 31].
In the MA-17 study of extended adjuvant therapy, use of letrozole led to a higher frequency of hot flashes compared with placebo (47% versus 41%, respectively) [24].